Tumor Type

United States
Non-Hodgkin Lymphoma - Diffuse large B cell lymphoma
Project Profile
Funding Organizations
Research Organizations
Research Activities
Publication Policy

1:   ICGC Goals, Structure, Policies and Guidelines Section E.3 - Publication Policy HTML 
2:   Template Letters to Facilitate Communications HTML 
to ensure appropriate dialogue between data users and generators and for authors to contact ICGC members and editors
Clinic & Pathology

United States: Broad Institute
Mayo Clinic
University of Iowa
Sequencing & Analysis

United States: Broad Institute
Dana-Farber Cancer Institute
Mayo Clinic
University of Iowa
Complementary Studies

Data Storage, Analysis & Management

United States: National Center for Biotechnology Information

Sequencing, SNP, copy number, and somatic variant calls will be stored at the NCBI short read archive as well as dbGAP for data sharing and distribution purposes.

Project Summary

Diffuse large B cell lymphoma is an aggressive Non-Hodgkin lymphoma that affects 30,000 new patients in the US every year. The standard of care for the treatment of most cases of DLBCL is chemo-immunotherapy with the “R-CHOP” regimen. Although the 3-year event-free survival is about 60% even for elderly patients between 60-80 years old, the remainder of patients eventually relapse and the majority die of their disease. To date, treatment strategies to improve outcome have largely included increased doses of standard agents in the context of autologous stem cell transplantation. Therefore, there is a great medical need to define the genetic abnormalities that are associated with DLBCL in order to define novel targets for therapy. We are undertaking an effort to characterize 100 DLBCL cases and matched normal controls using whole exome sequencing technology.

Slim Initiative for Genomic Medicine:

This work is conducted as part of the Slim Initiative for Genomic Medicine (SIGMA), a joint U.S.-Mexico project funded by the Carlos Slim Health Institute. The SIGMA cancer project aims to understand the genomic basis of cancer in worldwide populations by extensive analysis of at least 560 cancer pairs across at least 7 different cancers to obtain an initial molecular taxonomy of the mutations present in these cancer types.

Principal Investigators

Todd Golub
Jens Lohr
James Cerhan

Lead Jurisdiction